* Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤ 2.5 x upper limit of normal (ULN)
* Total bilirubin ≤ 1.5 mg/dl, except in individuals with Gilbert's syndrome.
* Cardiac ejection fraction ≥ 50%, no evidence of clinically significant pericardial effusion, and no clinically significant arrhythmias
* Baseline oxygen saturation \> 92% on room air
* QTc ≤ 500ms
* In individuals previously treated with blinatumomab, CD19 tumor expression in bone marrow or peripheral blood by flow cytometry or extramedullary site by IHC or flow cytometry
* Negative serum or urine beta-HCG test in females of childbearing potential within 3 weeks of enrollment
* Subjects of childbearing or child fathering potential must be willing to practice birth control from the time of enrollment on this study Page 10 of 83 Version 1.0 dated 27-April-2023 and for six (6) months after receiving the preparative conditioning regimen.
* Must be able to give informed consent. Legal authorized representative (LAR) is permitted if subject is cognitively able to provide verbal assent.
You may not be if
History of dasatinib intolerance
Known sensitivity or allergy to aminoglycosides or any agents/reagents used in this study
Blast count \> 75% in the bone marrow.
History of malignancy other than non-melanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) unless disease free for at least 2 years
Presence of CNS-3 disease with neurological changes
History or presence of any CNS disorder such as a seizure disorder, cerebrovascular ischemia/hemorrhage with clinical signs or symptoms
History of concomitant genetic syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman-Diamond or any known bone marrow failure syndrome
History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment
Primary immunodeficiency
Known infection with HIV, hepatitis B (HBsAg positive) or untreated hepatitis C virus
Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management.
Salvage chemotherapy including TKIs for Ph+ ALL within 1 week prior to enrollment
Pregnant or breast feeding
Patients with known autoimmune disease requiring the use of systemic immunosuppressive therapy within the last year
Corticosteroid therapy within 7 days prior to enrollment
Acute or chronic GVHD requiring systemic treatment within 4 weeks prior to enrollment
Live vaccine ≤ 4 weeks prior to enrollment
Any medical condition that in the judgement of the investigator is likely to interfere with assessment of safety or efficacy of study treatment
Clareo Health | Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia
